Literature DB >> 20133653

No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro.

Dylan W Peterson1, D Michael Ando, Daryl A Taketa, Hongjun Zhou, Fredrick W Dahlquist, John Lew.   

Abstract

CDK5/p35 is a cyclin-dependent kinase essential for normal neuron function. Proteolysis of the p35 subunit in vivo results in CDK5/p25 that causes neurotoxicity associated with a number of neurodegenerative diseases. Whereas the mechanism by which conversion of p35 to p25 leads to toxicity is unknown, there is common belief that CDK5/p25 is catalytically hyperactive compared to CDK5/p35. Here, we have compared the steady-state kinetic parameters of CDK5/p35 and CDK5/p25 towards both histone H1, the best known substrate for both enzymes, and the microtubule-associated protein, tau, a physiological substrate whose in vivo phosphorylation is relevant to Alzheimer's disease. We show that the kinetics of both enzymes are the same towards either substrate in vitro. Furthermore, both enzymes display virtually identical kinetics towards individual phosphorylation sites in tau monitored by NMR. We conclude that conversion of p35 to p25 does not alter the catalytic efficiency of the CDK5 catalytic subunit by using histone H1 or tau as substrates, and that neurotoxicity associated with CDK5/p25 is unlikely attributable to CDK5 hyperactivation, as measured in vitro.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20133653      PMCID: PMC2840295          DOI: 10.1073/pnas.0912718107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

1.  Characterization of the in vitro phosphorylation of human tau by tau protein kinase II (cdk5/p20) using mass spectrometry.

Authors:  E T Lund; R McKenna; D B Evans; S K Sharma; W R Mathews
Journal:  J Neurochem       Date:  2001-02       Impact factor: 5.372

2.  Neurotoxicity induces cleavage of p35 to p25 by calpain.

Authors:  M S Lee; Y T Kwon; M Li; J Peng; R M Friedlander; L H Tsai
Journal:  Nature       Date:  2000-05-18       Impact factor: 49.962

3.  Alzheimer disease specific phosphoepitopes of Tau interfere with assembly of tubulin but not binding to microtubules.

Authors:  Laziza Amniai; Pascale Barbier; Alain Sillen; Jean-Michel Wieruszeski; Vincent Peyrot; Guy Lippens; Isabelle Landrieu
Journal:  FASEB J       Date:  2008-12-12       Impact factor: 5.191

4.  Catalytic reaction pathway for the mitogen-activated protein kinase ERK2.

Authors:  C N Prowse; J C Hagopian; M H Cobb; N G Ahn; J Lew
Journal:  Biochemistry       Date:  2000-05-23       Impact factor: 3.162

5.  Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains.

Authors:  S Taniguchi; Y Fujita; S Hayashi; A Kakita; H Takahashi; S Murayama; T C Saido; S Hisanaga; T Iwatsubo; M Hasegawa
Journal:  FEBS Lett       Date:  2001-01-26       Impact factor: 4.124

6.  Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25.

Authors:  G Kusakawa; T Saito; R Onuki; K Ishiguro; T Kishimoto; S Hisanaga
Journal:  J Biol Chem       Date:  2000-06-02       Impact factor: 5.157

7.  Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain.

Authors:  A Takashima; M Murayama; K Yasutake; H Takahashi; M Yokoyama; K Ishiguro
Journal:  Neurosci Lett       Date:  2001-06-22       Impact factor: 3.046

8.  Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth.

Authors:  L R Zukerberg; G N Patrick; M Nikolic; S Humbert; C L Wu; L M Lanier; F B Gertler; M Vidal; R A Van Etten; L H Tsai
Journal:  Neuron       Date:  2000-06       Impact factor: 17.173

9.  Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration.

Authors:  G N Patrick; L Zukerberg; M Nikolic; S de la Monte; P Dikkes; L H Tsai
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

10.  Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions.

Authors:  M D Nguyen; R C Larivière; J P Julien
Journal:  Neuron       Date:  2001-04       Impact factor: 17.173

View more
  26 in total

1.  Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors.

Authors:  Joydev K Laha; Xuemei Zhang; Lixin Qiao; Min Liu; Snigdha Chatterjee; Shaughnessy Robinson; Kenneth S Kosik; Gregory D Cuny
Journal:  Bioorg Med Chem Lett       Date:  2011-02-03       Impact factor: 2.823

2.  Protein interaction module-assisted function X (PIMAX) approach to producing challenging proteins including hyperphosphorylated tau and active CDK5/p25 kinase complex.

Authors:  Dexin Sui; Xinjing Xu; Xuemei Ye; Mengyu Liu; Maxwell Mianecki; Chotirat Rattanasinchai; Christopher Buehl; Xiexiong Deng; Min-Hao Kuo
Journal:  Mol Cell Proteomics       Date:  2014-11-10       Impact factor: 5.911

3.  Quantum capacitance-limited MoS2 biosensors enable remote label-free enzyme measurements.

Authors:  Son T Le; Nicholas B Guros; Robert C Bruce; Antonio Cardone; Niranjana D Amin; Siyuan Zhang; Jeffery B Klauda; Harish C Pant; Curt A Richter; Arvind Balijepalli
Journal:  Nanoscale       Date:  2019-08-13       Impact factor: 7.790

4.  Spectroscopic studies of GSK3{beta} phosphorylation of the neuronal tau protein and its interaction with the N-terminal domain of apolipoprotein E.

Authors:  Arnaud Leroy; Isabelle Landrieu; Isabelle Huvent; Dominique Legrand; Bernadette Codeville; Jean-Michel Wieruszeski; Guy Lippens
Journal:  J Biol Chem       Date:  2010-08-02       Impact factor: 5.157

5.  Cdk5 phosphorylation of EFhd2 at S74 affects its calcium binding activity.

Authors:  Edwin Vázquez-Rosa; Eva N Rodríguez-Cruz; Sybelle Serrano; Lucelenie Rodríguez-Laureano; Irving E Vega
Journal:  Protein Sci       Date:  2014-06-18       Impact factor: 6.725

Review 6.  The role of Cdk5 in cognition and neuropsychiatric and neurological pathology.

Authors:  David G S Barnett; James A Bibb
Journal:  Brain Res Bull       Date:  2010-12-07       Impact factor: 4.077

7.  Schizophrenia is associated with dysregulation of a Cdk5 activator that regulates synaptic protein expression and cognition.

Authors:  Olivia Engmann; Tibor Hortobágyi; Ruth Pidsley; Claire Troakes; Hans-Gert Bernstein; Michael R Kreutz; Jonathan Mill; Margareta Nikolic; Karl Peter Giese
Journal:  Brain       Date:  2011-07-19       Impact factor: 13.501

8.  p10, the N-terminal domain of p35, protects against CDK5/p25-induced neurotoxicity.

Authors:  Lingyan Zhang; Wen Liu; Karen K Szumlinski; John Lew
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-14       Impact factor: 11.205

Review 9.  Cdk5 activity in the brain - multiple paths of regulation.

Authors:  Kavita Shah; Debomoy K Lahiri
Journal:  J Cell Sci       Date:  2014-06-01       Impact factor: 5.285

10.  Actin interaction and regulation of cyclin-dependent kinase 5/p35 complex activity.

Authors:  Jiqing Xu; Koji Tsutsumi; Kiyotaka Tokuraku; Katherine A Estes; Shin-ichi Hisanaga; Tsuneya Ikezu
Journal:  J Neurochem       Date:  2011-01       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.